Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3988/jcn.2017.13.2.155 http://scihub22266oqcxt.onion/10.3988/jcn.2017.13.2.155 C5392457!5392457!28271643     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Clin+Neurol 2017 ; 13 (2): 155-61 Nephropedia Template TP {{tp|p=28271643|t=2017. Rituximab Treatment for Idiopathic Hypertrophic Pachymeningitis |pdf=|usr=}}{{28271643}} gab.com Text Rituximab Treatment for Idiopathic Hypertrophic Pachymeningitis JO: J Clin Neurol http://www.kidney.de/pget.php?&tw=1&pmid=28271643 #FOAvip Background and Purpose: Hypertrophic pachymeningitis (HP) is a rare disease caused by autoimmunity in the meninx that causes various neurologic symptoms, including headache, seizures, weakness, paresthesia, and cranial nerve palsies. Although the first-line therapy for HP is steroids, many HP cases are refractory to steroids or recur when the steroids are tapered. Here we report three HP cases that were successfully treated with rituximab (RTX). Methods: From an institutional cohort recruited from April 2012 to July 2016, three HP cases that were identified to be steroid-refractory were treated with RTX (four weekly doses of 375 mg/m2). Clinical improvement was assessed by the number of relapses of any neurologic symptom and the largest dural thickness in MRI. Results: All three patients were recurrence-free of neurologic symptoms and exhibited prominent decreases in the dural thickness after RTX treatment. No adverse events were observed in the patients. Conclusions: We suggest RTX as a second-line therapy for steroid-refractory HP. Further studies are warranted to confirm this observation in a larger population and to consider RTX as a first-line therapy. Twit Text FOAVip Rituximab Treatment for Idiopathic Hypertrophic Pachymeningitis ????J Clin Neurol http://www.kidney.de/pget.php?&tw=1&pmid=28271643 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28271643 #FOAvip English Wikipedia <ref>{{Cite pmid|28271643}}</ref> Rituximab Treatment for Idiopathic Hypertrophic Pachymeningitis #MMPMID28271643 Jang Y; Lee ST; Jung KH; Chu K; Lee SK J Clin Neurol 2017[Apr]; 13 (2): 155-61 PMID28271643show ga Background and Purpose: Hypertrophic pachymeningitis (HP) is a rare disease caused by autoimmunity in the meninx that causes various neurologic symptoms, including headache, seizures, weakness, paresthesia, and cranial nerve palsies. Although the first-line therapy for HP is steroids, many HP cases are refractory to steroids or recur when the steroids are tapered. Here we report three HP cases that were successfully treated with rituximab (RTX). Methods: From an institutional cohort recruited from April 2012 to July 2016, three HP cases that were identified to be steroid-refractory were treated with RTX (four weekly doses of 375 mg/m2). Clinical improvement was assessed by the number of relapses of any neurologic symptom and the largest dural thickness in MRI. Results: All three patients were recurrence-free of neurologic symptoms and exhibited prominent decreases in the dural thickness after RTX treatment. No adverse events were observed in the patients. Conclusions: We suggest RTX as a second-line therapy for steroid-refractory HP. Further studies are warranted to confirm this observation in a larger population and to consider RTX as a first-line therapy. äRituximab Treatment for Idiopathic Hypertrophic Pachymeningitis (epmc).pdf DeepDyve Pubget Overpricing